CA19-9 as a serum marker for poor prognosis in urothelial carcinoma

被引：2
|
作者：
Suzuki, K [1 ]
机构：
[1] Jichi Med Sch, Dept Urol, Minami Kawachi, Tochigi 3290498, Japan
来源：
UROLOGIA INTERNATIONALIS | 2004年 / 73卷 / 04期
关键词：
D O I：
10.1159/000081599
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：357 / 357
页数：1
相关论文
共 50 条
  • [41] Pre-cystectomy serum levels of CA19-9, CA125, and CEA: Correlation with pathologic stage and oncologic outcome in urothelial carcinoma of bladder
    Ahmadi, Hamed
    Djaladat, Hooman
    Miranda, Gus
    Cai, Jie
    Daneshmand, Siamak
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [42] Elevated Serum CA19-9 in IPMN is a Highly-Specific Marker of Invasive Cancer and an Independent Predictor of Advanced Stage and Poor Survival
    Morales-Oyarvide, Vicente
    Mino-Kenudson, Mari
    Ferrone, Cristina R.
    Warshaw, Andrew L.
    Lillemoe, Keith D.
    Fernandez-del Castillo, Carlos
    GASTROENTEROLOGY, 2016, 150 (04) : S501 - S501
  • [43] The serum tumour marker Ca19-9 in non-small cell lung cancer (NSCLC)
    Vaslamatzis, Michael
    Patila, Elisabeth
    Margari, Charalampia P.
    Tegos, Theodoros K.
    Alevizopoulos, Nektarios
    Kyriakopoylos, Georgios
    Kyriou, Lamprini
    Laskarakis, Apostolos
    Kapou, Theodora
    Stathopoulos, Charalampos
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [44] Diagnostic Performance of a Tumor Marker Gene Test to Personalize Serum CA19-9 Reference Ranges
    Dbouk, Mohamad
    Abe, Toshiya
    Koi, Chiho
    Ando, Yohei
    Saba, Helena
    Abou Diwan, Elizabeth
    MacGregor-Das, Anne
    Blackford, Amanda L.
    Mocci, Evelina
    Beierl, Katie
    Dbouk, Ali
    He, Jin
    Burkhart, Richard
    Lennon, Anne Marie
    Sokoll, Lori
    Canto, Marcia Irene
    Eshleman, James R.
    Goggins, Michael
    CLINICAL CANCER RESEARCH, 2023, 29 (20) : 4178 - 4185
  • [45] Increased serum CA19-9 in patients with xanthogranulomatous cholecystitis
    Adachi, Y
    Iso, Y
    Moriyama, M
    Kasai, T
    Hashimoto, H
    HEPATO-GASTROENTEROLOGY, 1998, 45 (19) : 77 - 80
  • [46] Serum CA19-9 determination in the management of pancreatic cancer
    vandenBosch, RP
    vanEijck, CHJ
    Mulder, PGH
    Jeekel, J
    HEPATO-GASTROENTEROLOGY, 1996, 43 (09) : 710 - 713
  • [47] HIGH SERUM LEVELS OF CA19-9 IN ASYMPTOMATIC PATIENTS
    FISCHBACH, W
    MOSSNER, J
    KOCH, W
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1985, 110 (33) : 1274 - 1274
  • [48] Carcinomatous Meningitis and Hydrocephalus in Plasmacytoid Urothelial Carcinoma of the Urinary Bladder With Extremely Elevated CA19-9 Levels
    Henmi, Fumiaki
    Ukai, Kayako
    Nakayama, Atsuhito
    Takazawa, Yutaka
    Uesaka, Yoshikazu
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (02)
  • [49] EXPRESSION OF THE CARBOHYDRATE TUMOR MARKER SIALYL LEWIS A (CA19-9) IN SQUAMOUS CELL CARCINOMA OF THE LARYNX
    Wiest, I.
    Mayr, D.
    Alexiou, C.
    Schulze, S.
    Kuhn, C.
    Kunze, S.
    Buettner, M.
    Betz, P.
    Jeschke, U.
    ANTICANCER RESEARCH, 2008, 28 (6B) : 4013 - 4013
  • [50] Elevation of serum CA19-9 levels in benign diseases
    Ito, S
    Gejyo, F
    INTERNAL MEDICINE, 1999, 38 (11) : 840 - 841
12345